Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer

Objective: Sugemalimab is approved in China as a first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC). This study aims to evaluate the cost-effectiveness of first-line additional sugemalimab in combination with chemotherapy vs. chemother...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Zhiwei, Zhu, Huide, Fang, Ling, Cai, Hongfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511109/
https://www.ncbi.nlm.nih.gov/pubmed/36172187
http://dx.doi.org/10.3389/fphar.2022.996914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511109/
https://www.ncbi.nlm.nih.gov/pubmed/36172187
http://dx.doi.org/10.3389/fphar.2022.996914

Ejemplares similares